Max Augustin
Overview
Explore the profile of Max Augustin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1065
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmidt A, Casadei N, Brand F, Demidov G, Vojgani E, Abolhassani A, et al.
PLoS Pathog
. 2024 Dec;
20(12):e1012786.
PMID: 39715278
Courses of SARS-CoV-2 infections are highly variable, ranging from asymptomatic to lethal COVID-19. Though research has shown that host genetic factors contribute to this variability, cohort-based joint analyses of variants...
2.
Augustin M, Horn C, Ercanoglu M, Bondet V, de Silva U, Suarez I, et al.
Biomedicines
. 2024 Oct;
12(10).
PMID: 39457626
Background: Gastrointestinal mucosal damage due to human immunodeficiency virus (HIV) infection leads to microbial translocation and immune activation, contributing to the development of non-infectious comorbidities (NICM) in people living with...
3.
Hamdorf M, Imhof T, Bailey-Elkin B, Betz J, Theobald S, Simonis A, et al.
J Mol Cell Biol
. 2023 Oct;
15(10).
PMID: 37891014
The novel coronavirus pandemic, first reported in December 2019, was caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 infection leads to a strong immune response and activation...
4.
Augustin M, Stecher M, Wustenberg H, Di Cristanziano V, de Silva U, Picard L, et al.
Front Immunol
. 2023 Oct;
14:1226622.
PMID: 37781408
Background: While the short-term symptoms of post-COVID syndromes (PCS) are well-known, the long-term clinical characteristics, risk factors and outcomes of PCS remain unclear. Moreover, there is ongoing discussion about the...
5.
Kauer V, Totschnig D, Waldenberger F, Augustin M, Karolyi M, Nageli M, et al.
Viruses
. 2023 May;
15(5).
PMID: 37243267
Objective: The main goal of this study was to assess the potential clinical impact of an outpatient administration of available antivirals including SOT, N/R, and MOL to COVID-19 patients at...
6.
Augustin M, Heyn F, Ullrich S, de Silva U, Albert M, Linne V, et al.
Front Med (Lausanne)
. 2023 May;
10:1129288.
PMID: 37168268
Background: Symptoms lasting longer than 12 weeks after severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection are called post-coronavirus disease (COVID) syndrome (PCS). The identification of new biomarkers that...
7.
Augustin M, Hallek M, Nitschmann S
Inn Med (Heidelb)
. 2022 Nov;
63(12):1323-1326.
PMID: 36333431
No abstract available.
8.
Totschnig D, Augustin M, Niculescu I, Laferl H, Jansen-Skoupy S, Lehmann C, et al.
Viruses
. 2022 Oct;
14(10).
PMID: 36298832
Immunocompromised patients experience reduced vaccine effectiveness and are at higher risk for coronavirus disease 19 (COVID-19) death. Pre-exposure prophylaxis (PrEP) aims to protect these patients. So far, only tixagevimab/cilgavimab is...
9.
Augustin M, Hallek M, Nitschmann S
Inn Med (Heidelb)
. 2022 Aug;
63(8):900-902.
PMID: 35925069
No abstract available.
10.
Gruell H, Vanshylla K, Korenkov M, Tober-Lau P, Zehner M, Munn F, et al.
Cell Host Microbe
. 2022 Aug;
30(9):1231-1241.e6.
PMID: 35921836
SARS-CoV-2 neutralizing antibodies play a critical role in COVID-19 prevention and treatment but are challenged by viral evolution and the emergence of novel escape variants. Importantly, the recently identified Omicron...